Goyeneche AA

No ORCID on file · 9 papers in corpus · active 2007-2021

Study types

  • article 1
  • review 1

Condition tags

  • endometriosis 2
2021
Anticancer effects of mifepristone on human uveal melanoma cells.
Cancer cell international ·doi:10.1186/s12935-021-02306-y

BackgroundUveal melanoma (UM), the most prevalent intraocular tumor in adults, is a highly metastatic and drug resistant lesion. Recent studies have demonstrated cytotoxic and anti-metastatic effects of the antiprogestin and antiglucocortic…

article 2019
Reduced inflammatory state promotes reinnervation of endometriotic-like lesions in TNFRp55 deficient mice
Molecular human reproduction ·doi:10.1093/molehr/gaz026

Endometriosis is a chronic gynecological disease, characterized by growth of endometrial tissue in ectopic sites due to alteration of peritoneal homeostasis and deregulation of apoptosis. Here we have examined whether TNFRp55 deficiency mod…

review 2014
Antiprogestins in gynecological diseases
Reproduction (Cambridge, England) ·doi:10.1530/rep-14-0416

Antiprogestins constitute a group of compounds, developed since the early 1980s, that bind progesterone receptors with different affinities. The first clinical uses for antiprogestins were in reproductive medicine, e.g., menstrual regulatio…

2014
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
Journal of ovarian research ·doi:10.1186/1757-2215-7-45

BackgroundAntiprogestin compounds have been shown to be effective in blocking the growth of ovarian cancer cells of different genetic backgrounds. Herein we studied the anti-ovarian cancer effect of a series of antiprogestins sharing the ch…

2013
Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
BMC cancer ·doi:10.1186/1471-2407-13-35

BackgroundChanges in cell shape and plasticity in cytoskeletal dynamics are critically involved in cell adhesion, migration, invasion and the overall process of metastasis. Previous work in our laboratory demonstrated that the synthetic ste…

2012
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Investigational new drugs ·doi:10.1007/s10637-011-9655-z

Antiprogestins have been largely utilized in reproductive medicine, yet their repositioning for oncologic use is rapidly emerging. In this study we investigated the molecular mediators of the anti-ovarian cancer activity of the structurally…

2011
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
BMC cancer ·doi:10.1186/1471-2407-11-207

BackgroundMifepristone (MF) has been largely used in reproductive medicine due to its capacity to modulate the progesterone receptor (PR). The study of MF has been expanded to the field of oncology; yet it remains unclear whether the expres…

2009
Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.
International journal of oncology ·doi:10.3892/ijo_00000200

Repopulation of cancer cells escaping lethal chemotherapy is a critical factor hindering treatment success. One strategy to inhibit tumor cell repopulation is the use of cytostatic compounds between courses of lethal chemotherapy. In this s…

2007
Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-07-0164

PurposeThese studies were designed to determine whether the synthetic steroid mifepristone inhibits ovarian cancer growth in vitro and in vivo and the molecular mechanisms involved.Experimental designThe effect of mifepristone on ovarian ca…